These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25597319)

  • 1. [Assessment of risk factors for fractures in postmenopausal women with osteoporosis].
    Ferencz V; Horváth C; Huszár S; Bors K
    Orv Hetil; 2015 Jan; 156(4):146-53. PubMed ID: 25597319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing osteoporosis-related fractures: an overview.
    Gass M; Dawson-Hughes B
    Am J Med; 2006 Apr; 119(4 Suppl 1):S3-S11. PubMed ID: 16563939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis.
    Huang S; Lin H; Zhu X; Chen X; Fan L; Liu C
    Endokrynol Pol; 2014; 65(2):96-104. PubMed ID: 24802732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
    Siris ES; Baim S; Nattiv A
    Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal osteoporosis.
    Diab DL; Watts NB
    Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):501-9. PubMed ID: 24150190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of women at risk for fracture and intervention with fast-acting therapies.
    Derman R
    Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
    Boonen S; Klemes AB; Zhou X; Lindsay R
    J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year fracture risk in the assessment of osteoporosis management efficacy in postmenopausal women: a pilot study.
    Pluskiewicz W; Drozdzowska B; Adamczyk P
    Climacteric; 2013 Feb; 16(1):117-26. PubMed ID: 22335356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON.
    Popp AW; Buffat H; Cavelti A; Windolf M; Perrelet R; Senn C; Lippuner K
    Maturitas; 2014 Mar; 77(3):287-93. PubMed ID: 24485216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ten-year fracture risk by FRAX(®) of women with osteoporosis attending osteoporosis care in Hungary].
    Péntek M; Gulácsi L; Tóth E; Baji P; Brodszky V; Horváth C
    Orv Hetil; 2016 Jan; 157(4):146-53. PubMed ID: 26772827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture.
    Perreault S; Dragomir A; Blais L; Moride Y; Rossignol M; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):248-59. PubMed ID: 18213734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).
    Díez-Pérez A; Adachi JD; Adami S; Anderson FA; Boonen S; Chapurlat R; Compston JE; Cooper C; Gehlbach SH; Greenspan SL; Hooven FH; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Siris ES; Wyman A; Rushton-Smith SK; Watts NB;
    J Bone Miner Res; 2014 Jan; 29(1):260-7. PubMed ID: 23794198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
    Gorai I;
    Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).
    Jakob F; Marín F; Martín-Mola E; Torgerson D; Fardellone P; Adami S; Thalassinos NC; Sykes D; Melo-Gomes J; Chinn C; Nicholson T; Cooper C
    QJM; 2006 Aug; 99(8):531-43. PubMed ID: 16861718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis.
    Divittorio G; Jackson KL; Chindalore VL; Welker W; Walker JB
    Pharmacotherapy; 2006 Jan; 26(1):104-14. PubMed ID: 16506352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.